KalVista Pharmaceuticals (KALV) Expected to Announce Earnings on Tuesday

KalVista Pharmaceuticals (NASDAQ:KALV) is anticipated to release its Q4 2026 results after the market closes on Tuesday, March 24th. Analysts expect KalVista Pharmaceuticals to post earnings of ($0.5263) per share and revenue of $32.2860 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 1:00 AM ET.

KalVista Pharmaceuticals Trading Up 3.5%

Shares of KALV opened at $17.00 on Monday. The stock has a market capitalization of $859.35 million, a PE ratio of -4.30 and a beta of -0.35. The company’s fifty day moving average is $15.80 and its 200 day moving average is $14.38. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a fifty-two week low of $9.23 and a fifty-two week high of $19.00.

Analysts Set New Price Targets

A number of equities analysts have commented on KALV shares. HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Finally, Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.40.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 6,693 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $16.08, for a total value of $107,623.44. Following the sale, the chief executive officer directly owned 451,815 shares of the company’s stock, valued at $7,265,185.20. This represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul K. Audhya sold 5,354 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the sale, the insider directly owned 138,983 shares in the company, valued at $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,378 shares of company stock worth $522,290. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KALV. Invesco Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 23.1% during the 4th quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock worth $1,258,000 after acquiring an additional 14,621 shares during the last quarter. XTX Topco Ltd bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $428,000. Vestal Point Capital LP increased its stake in KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after purchasing an additional 1,140,000 shares during the period. Virtus Investment Advisers LLC increased its stake in KalVista Pharmaceuticals by 364.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock worth $653,000 after purchasing an additional 31,721 shares during the period. Finally, Squadron Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $11,305,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.